SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
-8.11%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$114M
AUM Growth
+$114M
(+1.8%)
Cap. Flow
+$18.5M
Cap. Flow
% of AUM
16.28%
Top 10 Holdings %
Top 10 Hldgs %
68.83%
Holding
46
New
19
Increased
9
Reduced
9
Closed
8
Top Buys
| 1 |
Cogent Biosciences
COGT
|
$7.1M |
| 2 |
IDEAYA Biosciences
IDYA
|
$5.84M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$5.09M |
| 4 |
Terns Pharmaceuticals
TERN
|
$3.72M |
| 5 |
UroGen Pharma
URGN
|
$3.21M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$5.85M |
| 2 |
Cytokinetics
CYTK
|
$4.06M |
| 3 |
Capricor Therapeutics
CAPR
|
$3.89M |
| 4 |
89bio
ETNB
|
$3.61M |
| 5 |
Nkarta
NKTX
|
$3.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Oric Pharmaceuticals
ORIC
$994M
| $12.8M | 11.05% | 1,580,745 +631,223 | +66% | +$5.09M |
|
|
2
Terns Pharmaceuticals
TERN
$609M
| $11.2M | 9.69% | 2,020,562 +672,016 | +50% | +$3.72M |
|
|
3
Zai Lab
ZLAB
$3.68B
| $10.6M | 9.15% | 403,630 -223,302 | -36% | -$5.85M |
|
4
NovoCure
NVCR
$1.38B
| $8.55M | 7.41% | 286,970 -105,741 | -27% | -$3.15M |
|
5
BridgeBio Pharma
BBIO
$9.89B
| $7.19M | 6.23% | 262,141 +35,457 | +16% | +$973K |
|
|
6
Cogent Biosciences
COGT
$1.69B
| $7.1M | 6.15% | +910,865 | New | +$7.1M |
|
|
7
Cytokinetics
CYTK
$4.23B
| $6.09M | 5.27% | 129,389 -86,409 | -40% | -$4.06M |
|
8
Structure Therapeutics
GPCR
$1.11B
| $5.88M | 5.09% | 216,811 -10,236 | -5% | -$278K |
|
|
9
IDEAYA Biosciences
IDYA
$2.15B
| $5.84M | 5.05% | +227,102 | New | +$5.84M |
|
|
10
UroGen Pharma
URGN
$900M
| $3.21M | 2.78% | +301,206 | New | +$3.21M |
|
11
Summit Therapeutics
SMMT
$17.6B
| $2.94M | 2.54% | +164,564 | New | +$2.94M |
|
12
Instil Bio
TIL
$182M
| $2.83M | 2.45% | 148,017 +40,472 | +38% | +$773K |
|
13
Protagonist Therapeutics
PTGX
$3.67B
| $2.66M | 2.3% | +68,892 | New | +$2.66M |
|
14
Insmed
INSM
$28.8B
| $2.48M | 2.15% | +35,966 | New | +$2.48M |
|
15
Fate Therapeutics
FATE
$120M
| $2.28M | 1.97% | 1,379,556 -87,378 | -6% | -$144K |
|
16
Legend Biotech
LEGN
$6.41B
| $2.26M | 1.96% | 69,594 +9,079 | +15% | +$295K |
|
17
Protara Therapeutics
TARA
$120M
| $1.9M | 1.65% | +360,000 | New | +$1.9M |
|
18
Cabaletta Bio
CABA
$133M
| $1.87M | 1.62% | 822,293 +690,498 | +524% | +$1.57M |
|
19
Dyne Therapeutics
DYN
$1.92B
| $1.72M | 1.49% | +73,150 | New | +$1.72M |
|
20
Savara
SVRA
$567M
| $1.56M | 1.35% | 508,338 +308,338 | +154% | +$947K |
|
21
Tango Therapeutics
TNGX
$747M
| $1.47M | 1.27% | 474,955 -124,093 | -21% | -$383K |
|
22
Kura Oncology
KURA
$686M
| $1.38M | 1.19% | +157,959 | New | +$1.38M |
|
23
Incyte
INCY
$16.5B
| $1.24M | 1.08% | +18,009 | New | +$1.24M |
|
|
ONC
24
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $1.18M | 1.02% | +6,365 | New | +$1.18M |
|
25
Verastem
VSTM
$569M
| $1.09M | 0.94% | +209,889 | New | +$1.09M |
|